NEW HAVEN, Conn., (WPRI) – A new study links radiation from cell phones to behavioral problems in the offspring of pregnant mice.

An illustration of the Lehigh mathematical model shows the evolution of Cdc42 distribution during cell growth, as cells transition toward a symmetric, or growth state. Credit: Lehigh University A collaboration between Lehigh University physicists and University of Miami biologists addresses an important fundamental question in basic cell biology: How do living cells figure out when and where to grow

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new clinical data highlighting the companys comprehensive cancer genomic profile and next-generation sequencing approach in clinical oncology will be presented at the 2012 Annual Meeting of the American Society for Clinical Oncology (ASCO) being held June 1-5, 2012 in Chicago. The data to be presented at ASCO support Foundation Medicines deep sequencing approach to simultaneously detect all classes of genomic alterations across hundreds of genes known to be related to cancer, said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine

ANN ARBOR, Mich., May 17, 2012 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM – News), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will be presenting at the World Stem Cells & Regenerative Medicine Congress at the Park Plaza hotel in London, UK.

IRVINE, Calif.–(BUSINESS WIRE)– California Stem Cell, Inc. (CSC) announced today that well-known stem cell & regenerative medicine industry veteran Gregory A.

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc.

17-05-2012 02:11 FOR MORE INFO MAIL TO drvikas0909@gmail.com,call:+918088878266 +919886871816

BOSTON (MarketWatch) — Shares of Osiris Therapeutics jumped 14% to $5.60 in after-hours trading Thursday on news that Canadian regulators have approved its product Prochymal for the treatment of acute graft-vs-host disease, or GVHD, in children. GVHD is a life-threatening complication associated with such procedures as bone-marrow transplantation.

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics Inc. (NASDAQ:OSIR – News) announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

Osiris Therapeutics Inc says Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient’s body.